{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:24:19Z","timestamp":1777692259987,"version":"3.51.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pneumococcal vaccines have been utilized in the United States for decades with extensive clinical safety records. However, comprehensive post-marketing pharmacovigilance evaluations for all available types remain lacking. This study aimed to assess adverse events following immunization (AEFI) using the VAERS database and analyze potential associations between adverse events (AEs) and vaccine administration based on VAERS data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrieved all AEs associated with pneumococcal vaccines recorded in the VAERS database from 1990 through March 2025. Descriptive analyses were conducted to summarize the demographics, clinical characteristics, and vaccination profiles of reported cases. Disproportionality analysis was performed to detect potential safety signals between AEs and vaccine administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The VAERS database documented 157,244 individuals receiving pneumococcal vaccines, with 158,778 doses administered, capturing 632,481 AE reports following vaccination during the study period. Females showed higher AE reporting rates (54.29%) compared to males (36.88%), with the majority of cases (38.20%) occurring in individuals aged &amp;lt; 18 years. Complete recovery (44.20%) and hospitalization (14.94%) were the most common outcomes. Most AEs (77.11%) occurred within 0\u201330 days post-vaccination (median onset: 0 day). Pneumococcal polysaccharide vaccine (PPSV, 48.92%) and 13-valent pneumococcal conjugate vaccine (PCV13, 27.57%) constituted the predominant vaccine types. Disproportionality analysis identified 929 positive AE signals across 24 system organ classes (SOCs), with injection site erythema [reporting odds ratio (ROR) = 4.24], injection site swelling (ROR = 4.19), and injection site pain (ROR = 2.75) being the most frequent. Designated Medical Event (DME) screening revealed erythema multiforme (n = 398) and product contamination microbial (ROR = 11.25) as key safety signals. General disorders (ROR = 1.73) and skin conditions (ROR = 1.69) were the predominant SOC categories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This post-marketing surveillance has revealed predominantly non-serious AEs, with most adverse events clustered within 30 days post-vaccination. These observations reinforce the established safety profile of pneumococcal vaccines while emphasizing temporal risk patterns to guide post-vaccination monitoring protocols and risk-benefit evaluations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1635180","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:28:09Z","timestamp":1756186089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing safety surveillance of pneumococcal vaccines: a real-world pharmacovigilance study using the U.S. vaccine adverse event reporting system (VAERS) database"],"prefix":"10.3389","volume":"15","author":[{"given":"Xinkuo","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meishen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanli","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalin","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2488189","DOI":"10.1080\/22221751.2025.2488189","article-title":"Serotype epidemiology and case-fatality risk of invasive pneumococcal disease: a nationwide population study from Switzerland, 2012-2022","volume":"14","author":"Albrich","year":"2025","journal-title":"Emerg. Microbes Infect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0377","article-title":"Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease","volume":"145","author":"Berman-Rosa","year":"2020","journal-title":"Pediatrics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B6","unstructured":"Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2022\n          \n          \n          \n          2022"},{"key":"B7","unstructured":"Manual for the surveillance of vaccine-preventable diseases\n          \n          \n          \n          2024"},{"key":"B8","article-title":"Surveillance for Safety After Immunization: Vaccine Adverse Event Reporting System (VAERS) --- United States. 1991--2001, 2003","year":"2003"},{"key":"B9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The vaccine adverse event reporting system (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"key":"B10","volume-title":"Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS\/WHO Working Group on Vaccine Pharmacovigilance","year":"2012"},{"key":"B11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1473-3099(18)30310-4","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1016\/j.vaccine.2016.10.052","article-title":"Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged \u2267\u033819years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","article-title":"Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance","volume":"39","author":"Heo","year":"2020","journal-title":"Stat. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1586\/14760584.2014.883285","article-title":"Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature","volume":"13","author":"Herzog","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3928\/0090-4481-20040901-11","article-title":"The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety","volume":"33","author":"Iskander","year":"2004","journal-title":"Pediatr. Ann."},{"key":"B19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3349\/ymj.2020.61.3.243","article-title":"Signal detection of adverse events following pneumococcal vaccines from the Korea adverse event reporting system database, 2005-2016","volume":"61","author":"Kim","year":"2020","journal-title":"Yonsei Med. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.15585\/mmwr.mm7137a3","article-title":"Use of 15-valent pneumococcal conjugate vaccine among U.S. Children: updated recommendations of the advisory committee on immunization practices - United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm7401a1","article-title":"Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged \u226550 years: recommendations of the advisory committee on immunization practices - United States, 2024","volume":"74","author":"Kobayashi","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the advisory committee on immunization practices, United States, 2023","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"100812","DOI":"10.1016\/j.lanepe.2023.100812","article-title":"Pneumococcal serotypes and risk factors in adult community-acquired pneumonia 2018-20; a multicentre UK cohort study","volume":"37","author":"Lansbury","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"B25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.seizure.2023.07.003","article-title":"Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system","volume":"110","author":"Liu","year":"2023","journal-title":"Seizure"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305892","article-title":"A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States","volume":"20","author":"Malik","year":"2025","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1016\/j.vaccine.2014.07.073","article-title":"The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.vaccine.2016.04.021","article-title":"Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013","volume":"34","author":"Miller","year":"2016","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41579-024-01116-z","article-title":"Streptococcus pneumoniae epidemiology, pathogenesis and control","volume":"23","author":"Narciso","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40264-024-01498-2","article-title":"Post-licensure safety surveillance of 20-valent pneumococcal conjugate vaccine (PCV20) among US adults in the vaccine adverse event reporting system (VAERS)","volume":"48","author":"Oliveira","year":"2025","journal-title":"Drug Saf."},{"key":"B31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/vaccines9080815","article-title":"Vaccinations and autoimmune diseases","volume":"9","author":"Olivieri","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"B32","doi-asserted-by":"publisher","first-page":"243","DOI":"10.12688\/f1000research","article-title":"Revised World Health Organization (WHO)\u2019s causality assessment of adverse events following immunization-a critique","volume":"7","author":"Puliyel","year":"2018","journal-title":"F1000Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41479-017-0030-5","article-title":"Pneumococcal conjugate vaccine implementation in middle-income countries","volume":"9","author":"Tricarico","year":"2017","journal-title":"Pneumonia (Nathan)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2460274","article-title":"Pneumococcal vaccines in China","volume":"21","author":"Wang","year":"2025","journal-title":"Hum. Vaccin Immunother."},{"key":"B38","first-page":"1","article-title":"Pneumococcal disease","volume":"29","year":"2024","journal-title":"epiTRENDS"},{"key":"B39","unstructured":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics (WHO\/EMP\/IAU\/2017.12)\n          \n          \n          \n          2017"},{"key":"B40","unstructured":"Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013 February 2019\n          \n          \n          \n          2019"},{"key":"B41","unstructured":"Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification\n          \n          2021"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1635180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T05:28:12Z","timestamp":1756186092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1635180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":41,"alternative-id":["10.3389\/fcimb.2025.1635180"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1635180","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1635180"}}